Phase II Trial of Chemotherapy plus Bevacizumab as Second-Line Therapy for Patients with Metastatic Colorectal Cancer That Progressed on Bevacizumab with Chemotherapy: The Gunma Clinical Oncology Group (GCOG) trial 001 SILK Study
- Author
- TSUTSUMI, Soichi1 ; ISHIBASHI, Keiichiro3 ; KUWANO, Hiroyuki1 ; UCHIDA, Nobuyuki4 ; OJIMA, Hitoshi5 ; HOSOUCHI, Yasuo2 ; YASHUDA, Naokuni6 ; KIGURE, Wakako1 ; YAMAUCHI, Satoru1 ; ASAO, Takayuki1 ; ISHIDA, Hideyuki3
[1] Department of General Surgical Science, Gunma University, Graduate School of Medicine, Japan
[2] Department of Surgery, Gunma Prefecture Saiseikai-Maebashi Hospital, Maebashi, Japan
[3] Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, Saitama, Japan
[4] Department of Surgery, Haramachi Red-Cross Hospital, Gunma, Japan
[5] Department of Surgery, Gunma Cancer Center, Ota City, Japan
[6] Department of Colorectal Surgery, Isesaki Municipal Hospital, Isesaki, Japan - Source
Oncology. 2012, Vol 83, Num 3, pp 151-157, 7 p ; ref : 22 ref
- ISSN
- 0030-2414
- Scientific domain
- Medical oncology
- Publisher
- Karger, Basel
- Publication country
- Switzerland
- Document type
- Article
- Language
- English
- Author keyword
- Bevacizumab Beyond progression Colorectal cancer
- Keyword (fr)
- Antiangiogénique Anticancéreux Bévacizumab Cancer colorectal Cancérologie Chimiothérapie Essai clinique phase II Essai clinique Facteur croissance endothélium vasculaire Homme Métastase Soie Stade avancé Traitement de deuxième intention Tumeur maligne Anti-VEGF Anticorps monoclonal Cancer Pathologie de l'appareil digestif Pathologie de l'intestin Pathologie du côlon Pathologie du rectum Traitement
- Keyword (en)
- Antiangiogenic agent Antineoplastic agent Bevacizumab Colorectal cancer Cancerology Chemotherapy Phase II trial Clinical trial Vascular endothelium growth factor Human Metastasis Silk Advanced stage Second line treatment Malignant tumor Monoclonal antibody Cancer Digestive diseases Intestinal disease Colonic disease Rectal disease Treatment
- Keyword (es)
- Antiangiogenico Anticanceroso Bevacizumab Cancer de colon y recto Cancerología Quimioterapia Ensayo clínico fase II Ensayo clínico Factor crecimiento endotelio vascular Hombre Metástasis Seda Estadio avanzado Tratamiento de segunda línea Tumor maligno Anticuerpo monoclonal Cáncer Aparato digestivo patología Intestino patología Colón patología Recto patología Tratamiento
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B13 Gastroenterology. Liver. Pancreas. Abdomen / 002B13B Stomach. Duodenum. Small intestine. Colon. Rectum. Anus / 002B13B01 Tumors
- Discipline
- Gastroenterology. Liver. Pancreas. Abdomen Tumours
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 26275509
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1159/000337992 
https://dx.doi.org/10.1159/000337992
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.1159\/000337992\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:229:\"Phase II Trial of Chemotherapy plus Bevacizumab as Second-Line Therapy for Patients with Metastatic Colorectal Cancer That Progressed on Bevacizumab with Chemotherapy: The Gunma Clinical Oncology Group (GCOG) trial 001 SILK Study\";s:9:\"\u0000*\u0000jtitle\";s:8:\"Oncology\";s:9:\"\u0000*\u0000stitle\";s:8:\"Oncology\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"83\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"151\";s:8:\"\u0000*\u0000epage\";s:3:\"157\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0030-2414\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"TSUTSUMI\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Soichi\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:20:\"ISHIBASHI, Keiichiro\";i:1;s:16:\"KUWANO, Hiroyuki\";i:2;s:16:\"UCHIDA, Nobuyuki\";i:3;s:14:\"OJIMA, Hitoshi\";i:4;s:15:\"HOSOUCHI, Yasuo\";i:5;s:16:\"YASHUDA, Naokuni\";i:6;s:14:\"KIGURE, Wakako\";i:7;s:16:\"YAMAUCHI, Satoru\";i:8;s:14:\"ASAO, Takayuki\";i:9;s:16:\"ISHIDA, Hideyuki\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:229:\"Phase II Trial of Chemotherapy plus Bevacizumab as Second-Line Therapy for Patients with Metastatic Colorectal Cancer That Progressed on Bevacizumab with Chemotherapy: The Gunma Clinical Oncology Group (GCOG) trial 001 SILK Study\";s:8:\"\u0000*\u0000place\";s:5:\"Basel\";s:6:\"\u0000*\u0000pub\";s:6:\"Karger\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.1159\/000337992\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:229:\"Phase II Trial of Chemotherapy plus Bevacizumab as Second-Line Therapy for Patients with Metastatic Colorectal Cancer That Progressed on Bevacizumab with Chemotherapy: The Gunma Clinical Oncology Group (GCOG) trial 001 SILK Study\";s:9:\"\u0000*\u0000jtitle\";s:8:\"Oncology\";s:9:\"\u0000*\u0000stitle\";s:8:\"Oncology\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"83\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"151\";s:8:\"\u0000*\u0000epage\";s:3:\"157\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0030-2414\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"TSUTSUMI\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Soichi\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:20:\"ISHIBASHI, Keiichiro\";i:1;s:16:\"KUWANO, Hiroyuki\";i:2;s:16:\"UCHIDA, Nobuyuki\";i:3;s:14:\"OJIMA, Hitoshi\";i:4;s:15:\"HOSOUCHI, Yasuo\";i:5;s:16:\"YASHUDA, Naokuni\";i:6;s:14:\"KIGURE, Wakako\";i:7;s:16:\"YAMAUCHI, Satoru\";i:8;s:14:\"ASAO, Takayuki\";i:9;s:16:\"ISHIDA, Hideyuki\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:229:\"Phase II Trial of Chemotherapy plus Bevacizumab as Second-Line Therapy for Patients with Metastatic Colorectal Cancer That Progressed on Bevacizumab with Chemotherapy: The Gunma Clinical Oncology Group (GCOG) trial 001 SILK Study\";s:8:\"\u0000*\u0000place\";s:5:\"Basel\";s:6:\"\u0000*\u0000pub\";s:6:\"Karger\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:17:\"10.1159\/000337992\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.1159\/000337992\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:229:\"Phase II Trial of Chemotherapy plus Bevacizumab as Second-Line Therapy for Patients with Metastatic Colorectal Cancer That Progressed on Bevacizumab with Chemotherapy: The Gunma Clinical Oncology Group (GCOG) trial 001 SILK Study\";s:9:\"\u0000*\u0000jtitle\";s:8:\"Oncology\";s:9:\"\u0000*\u0000stitle\";s:8:\"Oncology\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"83\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"151\";s:8:\"\u0000*\u0000epage\";s:3:\"157\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0030-2414\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"TSUTSUMI\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Soichi\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:20:\"ISHIBASHI, Keiichiro\";i:1;s:16:\"KUWANO, Hiroyuki\";i:2;s:16:\"UCHIDA, Nobuyuki\";i:3;s:14:\"OJIMA, Hitoshi\";i:4;s:15:\"HOSOUCHI, Yasuo\";i:5;s:16:\"YASHUDA, Naokuni\";i:6;s:14:\"KIGURE, Wakako\";i:7;s:16:\"YAMAUCHI, Satoru\";i:8;s:14:\"ASAO, Takayuki\";i:9;s:16:\"ISHIDA, Hideyuki\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:229:\"Phase II Trial of Chemotherapy plus Bevacizumab as Second-Line Therapy for Patients with Metastatic Colorectal Cancer That Progressed on Bevacizumab with Chemotherapy: The Gunma Clinical Oncology Group (GCOG) trial 001 SILK Study\";s:8:\"\u0000*\u0000place\";s:5:\"Basel\";s:6:\"\u0000*\u0000pub\";s:6:\"Karger\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.1159\/000337992\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:229:\"Phase II Trial of Chemotherapy plus Bevacizumab as Second-Line Therapy for Patients with Metastatic Colorectal Cancer That Progressed on Bevacizumab with Chemotherapy: The Gunma Clinical Oncology Group (GCOG) trial 001 SILK Study\";s:9:\"\u0000*\u0000jtitle\";s:8:\"Oncology\";s:9:\"\u0000*\u0000stitle\";s:8:\"Oncology\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"83\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"151\";s:8:\"\u0000*\u0000epage\";s:3:\"157\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0030-2414\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"TSUTSUMI\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Soichi\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:20:\"ISHIBASHI, Keiichiro\";i:1;s:16:\"KUWANO, Hiroyuki\";i:2;s:16:\"UCHIDA, Nobuyuki\";i:3;s:14:\"OJIMA, Hitoshi\";i:4;s:15:\"HOSOUCHI, Yasuo\";i:5;s:16:\"YASHUDA, Naokuni\";i:6;s:14:\"KIGURE, Wakako\";i:7;s:16:\"YAMAUCHI, Satoru\";i:8;s:14:\"ASAO, Takayuki\";i:9;s:16:\"ISHIDA, Hideyuki\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:229:\"Phase II Trial of Chemotherapy plus Bevacizumab as Second-Line Therapy for Patients with Metastatic Colorectal Cancer That Progressed on Bevacizumab with Chemotherapy: The Gunma Clinical Oncology Group (GCOG) trial 001 SILK Study\";s:8:\"\u0000*\u0000place\";s:5:\"Basel\";s:6:\"\u0000*\u0000pub\";s:6:\"Karger\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.1159\/000337992\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:229:\"Phase II Trial of Chemotherapy plus Bevacizumab as Second-Line Therapy for Patients with Metastatic Colorectal Cancer That Progressed on Bevacizumab with Chemotherapy: The Gunma Clinical Oncology Group (GCOG) trial 001 SILK Study\";s:9:\"\u0000*\u0000jtitle\";s:8:\"Oncology\";s:9:\"\u0000*\u0000stitle\";s:8:\"Oncology\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"83\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"151\";s:8:\"\u0000*\u0000epage\";s:3:\"157\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0030-2414\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"TSUTSUMI\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Soichi\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:20:\"ISHIBASHI, Keiichiro\";i:1;s:16:\"KUWANO, Hiroyuki\";i:2;s:16:\"UCHIDA, Nobuyuki\";i:3;s:14:\"OJIMA, Hitoshi\";i:4;s:15:\"HOSOUCHI, Yasuo\";i:5;s:16:\"YASHUDA, Naokuni\";i:6;s:14:\"KIGURE, Wakako\";i:7;s:16:\"YAMAUCHI, Satoru\";i:8;s:14:\"ASAO, Takayuki\";i:9;s:16:\"ISHIDA, Hideyuki\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:229:\"Phase II Trial of Chemotherapy plus Bevacizumab as Second-Line Therapy for Patients with Metastatic Colorectal Cancer That Progressed on Bevacizumab with Chemotherapy: The Gunma Clinical Oncology Group (GCOG) trial 001 SILK Study\";s:8:\"\u0000*\u0000place\";s:5:\"Basel\";s:6:\"\u0000*\u0000pub\";s:6:\"Karger\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
